2,2,2',2'-tetramethyl-3,3'-o-phenylene-di-propionic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2,2,2',2'-tetramethyl-3,3'-o-phenylene-di-propionic acid
• 英文别名: o-Xylylen-bis-dimethylessigsaeure；2,2,2',2'-Tetramethyl-3,3'-o-phenylen-di-propionsaeure；3-[2-(2-Carboxy-2-methylpropyl)phenyl]-2,2-dimethylpropanoic acid；3-[2-(2-carboxy-2-methylpropyl)phenyl]-2,2-dimethylpropanoic acid
• 化学式: C₁₆H₂₂O₄
• 分子量: 278.348
• InChiKey: SWKASQGIPGKRMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2-bis-(2,2-dimethyl-3-oxo-3-phenyl-propyl)-benzene 在 硫酸 、 sodium amide 、 xylene 作用下， 生成 2,2,2',2'-tetramethyl-3,3'-o-phenylene-di-propionic acid
  参考文献：
  名称：

  Dumesnil, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1913, vol. 157, p. 54

  摘要：

  DOI：

文献信息

• PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE
  申请人：Council of Scientific & Industrial Research

  公开号：US20140243537A1

  公开（公告）日：2014-08-28

  The present invention discloses high yielding enantioselective process for synthesis of Oseltamivir from readily available starting material, cis-1,4-butene diol. The process features incorporation of chirality using sharpless asymmetric epoxidation (AE) and diastereoselective Barbier allylation and construction of cyclohexene carboxylic acid ester core through a ring closing metathesis (RCM) reaction. Further also disclosed herein is synthesis of (−)-methyl 3-epi-shikimate.

  本发明揭示了一种高产高对映选择性的奥司他韦合成工艺，从易得的起始物质顺式-1,4-丁二醇出发。该工艺采用Sharpless不对称环氧化（AE）和立体选择性的Barbier烯丙基化，通过环内酯交换反应（RCM）构建环己烯羧酸酯核心以引入手性。此外，还揭示了(−)-甲基3-epi-香椿糖酸的合成。
• Dipivefrin orally disintegrating tablet formulations
  申请人：INSIGNIS THERAPEUTICS, INC.

  公开号：US11213484B2

  公开（公告）日：2022-01-04

  This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.

  本公开提供了口腔崩解地匹福林片剂（ODT）制剂，包括含有盐酸地匹福林的ODT制剂。本公开的 ODT 制剂包括 10% 至 70% 的粘合剂（重量百分比）、5% 至 50% 的基质成形剂（重量百分比）和 1% 至 20% 的掩味剂（重量百分比）。本公开的 ODT 制剂在给药时可迅速为患者提供肾上腺素。本公开还提供了一种治疗方法，通过向患有对肾上腺素有反应的疾病（如心脏病、哮喘、咳嗽、癌症、微生物感染、阿狄森氏病或过敏反应，特别是过敏性休克）的患者施用口腔崩解地匹福林片剂制剂来治疗该患者。
• DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS
  申请人：INSIGNIS THERAPEUTICS, INC.

  公开号：US20200276114A1

  公开（公告）日：2020-09-03

  This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.